On September 24, 2024, Madge Shafmaster, Director at ProMIS Neurosciences Inc (PMN, Financial), purchased 200,000 shares of the company, as reported in a recent SEC Filing. This transaction increased the insider's holdings to 208,333 shares.
ProMIS Neurosciences Inc is engaged in the discovery and development of precision treatments for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The shares were bought at a price of $1.28 each, valuing the transaction at $256,000. Following this purchase, the market cap of ProMIS Neurosciences Inc stands at $38.852 million.
Over the past year, the insider has bought a total of 200,000 shares and has not sold any shares. The insider transaction history for ProMIS Neurosciences Inc shows a pattern of more insider buying than selling, with 3 insider buys and 0 insider sells over the last year.
This insider buying activity could be of interest to investors, as it may signal confidence in the company's future prospects. For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors are encouraged to visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
